Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...

News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (NASDAQ: ...

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...

Shares of Prime Medicine ( PRME 13.07%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Prime Editing has potential to be best-in-class approach for AATD ---- Previously undisclosed program now emerging from within liver platform; ...

The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

Chardan analyst Geulah Livshits raised the firm’s price target on Prime Medicine (PRME) to $16 from $15 and keeps a Buy rating on the shares.